Advertisement

Does Supplementation with Omega-3 PUFAs Add to the Prevention of Cardiovascular Disease?

  • Evangelos C. Rizos
  • Moses S. Elisaf
Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Lipid Abnormalities and Cardiovascular Prevention

Abstract

Purpose of Review

Omega-3 fatty acids are increasingly used for the protection of cardiovascular disease. The main but not the sole mechanism of action is the reduction of triglyceride levels. In this review, we summarize the effect of omega-3 supplements on all-cause and cardiovascular mortality, myocardial infarction, and stroke from the relevant randomized controlled trials.

Recent Findings

Twenty-one randomized controlled trials assessed omega-3 supplementation on mortality and cardiovascular-related outcomes. From these studies, as well as from the relevant meta-analyses, we found that omega-3 supplements do not exert a consistent benefit for cardiovascular protection.

Summary

There is uncertainty of a clear profit from omega-3 supplementation in cardiovascular disease.

Keywords

Omega 3 Polyunsaturated fatty acids Fish oil Cardiovascular Myocardial infarction Death 

Notes

Compliance with Ethical Standards

Conflict of Interest

Both authors comply with ethical standards and are in line with best practices and codes of conduct of relevant professional bodies and/or national and international regulatory bodies. This study was not funded. The authors have received no payment in preparation of this manuscript. Evangelos C. Rizos and Moses S. Elisaf have given talks, attended conferences, and participated in trials and advisory boards sponsored by various pharmaceutical companies (Novartis, Sanofi, NovoNordisk, Pfizer, AstraZeneca/BMS, Eli Lilly, MSD/Vianex, Boehringer Ing, Amgen, GSK, Plus Pharmaceuticals, WinMedica, Elpen etc.).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • Alexander DD, Miller PE, Van Elswyk ME, Kuratko CN, Bylsma LC. A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk. Mayo Clin Proc. 2017;92(1):15–29. The latest meta-analysis on the field Google Scholar
  2. 2.
    Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Trikalinos T.A., Lee J., Moorthy D., Yu W.W., Lau J., Lichtenstein A.H., Chung M., 2012. Effects of eicosapentanoic acid and docosahexanoic acid on mortality across diverse settings: systematic review and meta-analysis of randomized trials and prospective cohorts. Rockville (MD): Agency for Healthcare Research and Quality (US).Google Scholar
  4. 4.
    Kwak SM, Myung SK, Lee YJ, Seo HG, for the Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (Eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172:686–94.CrossRefPubMedGoogle Scholar
  5. 5.
    Rizos EC, Ntzani EE. ω-3 fatty acids and lutein + Zeaxanthin supplementation for the prevention of cardiovascular disease. JAMA Intern Med. 2014;174(5):771–2.CrossRefPubMedGoogle Scholar
  6. 6.
    Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM, Authors/Task Force Members. 2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.CrossRefPubMedGoogle Scholar
  7. 7.
    Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL, Authors/Task Force Members.; Additional Contributor. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.CrossRefPubMedGoogle Scholar
  8. 8.
    Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–S45.CrossRefPubMedGoogle Scholar
  9. 9.
    Food and Drug Administration. Lovaza: GlaxoSmithKline. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021654s034lbl.pdf. Accessed December 20, 2016.
  10. 10.
    Electronic Medicines Compendium. Omacor: Abbott Healthcare Products Limited. http://www.medicines.org.uk/emc/medicine/10312 /indications. Accessed December 20, 2016.
  11. 11.
    Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376(9740):540–50.CrossRefPubMedGoogle Scholar
  12. 12.
    Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008;197:12–24.CrossRefPubMedGoogle Scholar
  13. 13.
    Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–57.CrossRefPubMedGoogle Scholar
  14. 14.
    Plutzky J. Atherosclerotic plaque rupture: emerging insights and opportunities. Am J Cardiol. 1999;84:15–20.CrossRefGoogle Scholar
  15. 15.
    Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet. 2003;361:477–85.CrossRefPubMedGoogle Scholar
  16. 16.
    Leifert WR, McMurchie EJ, Saint DA. Inhibition of cardiac sodium currents in adult rat myocytes by n-3 polyunsaturated fatty acids. J Physiol. 1999;520:671–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Leifert WR, Jahangiri A, McMurchie EJ. Membrane fluidity changes are associated with the antiarrhythmic effects of docosahexaenoic acid in adult rat cardiomyocytes. J Nutr Biochem. 2000;11:38–44.CrossRefPubMedGoogle Scholar
  18. 18.
    Xiao YF, Wright SN, Wang GK, Morgan JP, Leaf A. Fatty acids suppress voltage-gated Na+ currents in HEK293t cells transfected with the alpha subunit of the human cardiac sodium channel. Proc Natl Acad Sci. 1998;95:2680–5.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sakabe M, Shiroshita-Takeshita A, Maguy A, Dumesnil C, Nigam A, Leung TK, Nattel S. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation. 2007;116:2101–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O’Gara PT, Page RL, Tavazzi L, Tognoni G, OPERA Investigators. Fish oil and postoperative atrial fibrillation: the omega-3 fatty acids for prevention of post-operative atrial fibrillation (OPERA) randomized trial. JAMA. 2012;308:2001–11.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care. 2006;9:95–104.CrossRefPubMedGoogle Scholar
  22. 22.
    Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: meta-regression analysis of randomized trials. J Hypertens. 2002;20:1493–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Rees D, Miles EA, Banerjee T. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr. 2006;83:331–42.PubMedGoogle Scholar
  24. 24.
    Calder PC. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie. 2009;91:791–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC, HARP Research Group. Controlled trial of fish oil for regression of human coronary atherosclerosis. J Am Coll Cardiol. 1995;25(7):1492–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival. Cardiovasc Drugs Ther. 1997;11(3):485–91.CrossRefPubMedGoogle Scholar
  27. 27.
    Leng GC, Lee AJ, Fowkes FG, et al. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. Clin Nutr. 1998;17(6):265–71.CrossRefPubMedGoogle Scholar
  28. 28.
    von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis: a randomized, double blind, placebo-controlled trial. Ann Intern Med. 1999;130(7):554–62.CrossRefGoogle Scholar
  29. 29.
    Marchioli R, Barzi F, Bomba E, et al; GISSI-prevenzione investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105(16):1897–1903.Google Scholar
  30. 30.
    Nilsen DW, Albrektsen G, Landmark K, Moen S, Aarsland T, Woie L. Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr. 2001;74(1):50–6.PubMedGoogle Scholar
  31. 31.
    Leaf A, Albert CM, Josephson M, et al; Fatty acid antiarrhythmia trial investigators. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005; 112(18):2762–2768.Google Scholar
  32. 32.
    Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005;293(23):2884–91.CrossRefPubMedGoogle Scholar
  33. 33.
    Brouwer IA, Zock PL, Camm AJ, SOFA Study Group, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the study on omega-3 fatty acids and ventricular arrhythmia (SOFA) randomized trial. JAMA. 2006;295(22):2613–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Svensson M, Schmidt EB, Jørgensen KA, Christensen JH, OPACH Study Group. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol. 2006;1(4):780–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Yokoyama M, Origasa H, Matsuzaki M, et al; Japan EPA lipid intervention study (JELIS) investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007; 369(9567):1090–1098.Google Scholar
  36. 36.
    Tavazzi L, Maggioni AP, Marchioli R, et al; GISSI HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo controlled trial. Lancet 2008; 372(9645):1223–1230.Google Scholar
  37. 37.
    Garbagnati F, Cairella G, De Martino A, et al. Is antioxidant and n-3 supplementation able to improve functional status in poststroke patients? Results from the Nutristroke trial. Cerebrovasc Dis. 2009;27(4):375–83.CrossRefPubMedGoogle Scholar
  38. 38.
    Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S, SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363(21):2015–2026.Google Scholar
  40. 40.
    Rauch B, Schiele R, Schneider S, OMEGA Study Group, et al. OMEGA, a randomized, placebo controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Einvik G, Klemsdal TO, Sandvik L, Hjerkinn EM. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Cardiovasc Prev Rehabil. 2010;17(5):588–92.CrossRefPubMedGoogle Scholar
  42. 42.
    Bosch J, Gerstein HC, Dagenais GR, et al; ORIGIN trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012; 367(4):309–318.Google Scholar
  43. 43.
    Roncaglioni MC, Tombesi M, Avanzini F, et al. N-3 fatty acids in patients with multiple cardiovascular risk factors. Risk and prevention study collaborative group. N Engl J Med. 2013;368(19):1800–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Macchia A, Grancelli H, Varini S, et al; GESICA Investigators. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fibrillation) trial. J Am Coll Cardiol 2013; 61(4):463–468.Google Scholar
  45. 45.
    Bonds DE, Harrington M, Worrall BB, et al. Writing group for the AREDS2 Research Group. Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Intern Med 2014; 174(5):763–771.Google Scholar
  46. 46.
    Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. HPS2-THRIVE collaborative group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12.CrossRefPubMedGoogle Scholar
  47. 47.
    • Kantor ED, Rehm CD, Du M, White E, Giovannucci EL. Trends in dietary supplement use among US adults from 1999-2012. JAMA. 2016;316(14):1464–74. Real-world data show increasingly used omega-3 formulations Google Scholar
  48. 48.
    Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176(4):473–82.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Internal MedicineUniversity Hospital of IoanninaIoanninaGreece
  2. 2.University of Cyprus Medical SchoolNicosiaCyprus
  3. 3.University of Ioannina Medical SchoolIoanninaGreece

Personalised recommendations